PCPC, CHPA Urge Stretching Sunscreen Ingredient Safety Data Net
This article was originally published in The Rose Sheet
Executive Summary
PCPC and CHPA submit comments to FDA on Sunscreen Innovation Act compliance draft guidances. The groups ask the agency to expand the categories of data sufficient to support sunscreen ingredients as GRASE and suggest augmenting NDAC deliberations with input from toxicologists and biologists.
You may also be interested in...
FDA Drafts Guidance On Safety-Data Musts For GRASE Sunscreen Actives
Time and extent applicants seeking GRASE status for UV filters should provide FDA with the kind of clinical safety data used to support approval of chronic-use cutaneous drug products, and nonclinical testing should focus on potential long-term adverse effects, according to newly released draft guidance required from the agency under the Sunscreen Innovation Act. FDA is particularly interested in receiving comments about final formulation safety testing it anticipates requiring under specified monograph conditions.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.